These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 17703224)

  • 1. HIV-1 over time: fitness loss or robustness gain?
    Rolland M; Brander C; Nickle DC; Herbeck JT; Gottlieb GS; Campbell MS; Maust BS; Mullins JI
    Nat Rev Microbiol; 2007 Sep; 5(9):C1. PubMed ID: 17703224
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral and host determinants of HIV-1 pathogenesis.
    Van de Perre P
    AIDS; 2006 Apr; 20(6):933-4. PubMed ID: 16549980
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug induced superinfection in HIV and the evolution of drug resistance.
    Leontiev VV; Maury WJ; Hadany L
    Infect Genet Evol; 2008 Jan; 8(1):40-50. PubMed ID: 18024234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1.
    Kupfer B; Sing T; Schüffler P; Hall R; Kurz R; McKeown A; Schneweis KE; Eberl W; Oldenburg J; Brackmann HH; Rockstroh JK; Spengler U; Däumer MP; Kaiser R; Lengauer T; Matz B
    J Med Virol; 2007 Nov; 79(11):1629-39. PubMed ID: 17854039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the sequence space available for HIV-1 evolution.
    ter Brake O; von Eije KJ; Berkhout B
    AIDS; 2008 Sep; 22(14):1875-7. PubMed ID: 18753935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral fitness estimation using exchangeable on subsets priors and prior model selection.
    Kitchen CM; Weiss RE; Liu G; Wrin T
    Stat Med; 2007 Feb; 26(5):975-90. PubMed ID: 16755527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS: prehistory of HIV-1.
    Sharp PM; Hahn BH
    Nature; 2008 Oct; 455(7213):605-6. PubMed ID: 18833267
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired fitness.
    Sanchez-Merino V; Farrow MA; Brewster F; Somasundaran M; Luzuriaga K
    J Infect Dis; 2008 Jan; 197(2):300-8. PubMed ID: 18177249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of HIV-1 in a patient population failing multiple-drug therapy.
    Hong S; Cao J; Tu YT
    Microbiol Immunol; 2009 Sep; 53(9):535-9. PubMed ID: 19703248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of HIV-1 within-host evolution on transmission dynamics.
    Theys K; Libin P; Pineda-Peña AC; Nowé A; Vandamme AM; Abecasis AB
    Curr Opin Virol; 2018 Feb; 28():92-101. PubMed ID: 29275182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV "new strain" story: for more information.
    James JS
    AIDS Treat News; 2005 Jan; (409):3. PubMed ID: 15791711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM5alpha-independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells.
    Nakayama EE; Shingai Y; Kono K; Shioda T
    Virology; 2008 Jun; 375(2):514-20. PubMed ID: 18367226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env.
    Mens H; Jørgensen LB; Kronborg G; Schønning K; Benfield T
    Antivir Ther; 2009; 14(3):413-22. PubMed ID: 19474475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 tropism, disease progression, and clinical management.
    Burger H; Hoover D
    J Infect Dis; 2008 Oct; 198(8):1095-7. PubMed ID: 18783314
    [No Abstract]   [Full Text] [Related]  

  • 18. Estimating the date of origin of an HIV-1 circulating recombinant form.
    Tee KK; Pybus OG; Parker J; Ng KP; Kamarulzaman A; Takebe Y
    Virology; 2009 Apr; 387(1):229-34. PubMed ID: 19272628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
    Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
    Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.